Veeco Instruments Inc. (Nasdaq: VECO) today announced financial
results for its second quarter ended June 30, 2023. Results are
reported in accordance with U.S. generally accepted accounting
principles (“GAAP”) and are also reported adjusting for certain
items (“Non-GAAP”). A reconciliation between GAAP and Non-GAAP
operating results is provided at the end of this press release.
|
U.S. Dollars in millions, except per share data |
GAAP Results |
|
Q2 '23 |
|
Q2 '22 |
Revenue |
|
$ |
161.6 |
|
|
$ |
164.0 |
|
Net income (loss) |
|
$ |
(85.3 |
) |
|
$ |
9.7 |
|
Diluted earnings (loss) per
share |
|
$ |
(1.61 |
) |
|
$ |
0.18 |
|
|
|
|
|
|
|
|
|
|
Non-GAAP Results |
|
Q2 '23 |
|
Q2 '22 |
Operating income |
|
$ |
24.3 |
|
|
$ |
23.0 |
|
Net income |
|
$ |
20.6 |
|
|
$ |
20.0 |
|
Diluted earnings per
share |
|
$ |
0.36 |
|
|
$ |
0.35 |
|
|
|
|
|
|
|
|
|
|
“Veeco had another solid quarter with strong top and bottom-line
Non-GAAP results driven by record Semiconductor revenue,” commented
Bill Miller, Ph.D., Veeco’s Chief Executive Officer. “We continue
to execute our Laser Annealing growth strategy in advanced node
logic and memory by winning new customers and applications.”
“Veeco is uniquely positioned with differentiated technologies
in secular growth markets. Looking ahead, we expect opportunities
for our technologies to grow as customers continue to adopt our
products for their most advanced node devices used for
high-performance computing and artificial intelligence.”
Guidance and Outlook
The following guidance is provided for Veeco’s third quarter
2023:
- Revenue is expected in the range of $155 million to $175
million
- GAAP diluted earnings per share are expected in the range of
$0.16 to $0.27
- Non-GAAP diluted earnings per share are expected in the range
of $0.30 to $0.40
Conference Call Information
A conference call reviewing these results has
been scheduled for today, August 7, 2023 starting at 5:00pm ET. To
join the call, dial 1-877-407-8029 (toll-free) or 1-201-689-8029.
Participants may also access a live webcast of the call by visiting
the investor relations section of Veeco's website at ir.veeco.com.
A replay of the webcast will be made available on the Veeco website
that evening. We will post an accompanying slide
presentation to our website prior to the beginning of the
call.
About Veeco
Veeco (NASDAQ: VECO) is an innovative
manufacturer of semiconductor process equipment. Our laser
annealing, ion beam, chemical vapor deposition (CVD), metal organic
chemical vapor deposition (MOCVD), single wafer etch & clean
and lithography technologies play an integral role in the
fabrication and packaging of advanced semiconductor devices. With
equipment designed to optimize performance, yield and cost of
ownership, Veeco holds leading technology positions in the markets
we serve. To learn more about Veeco’s systems and service
offerings, visit www.veeco.com.
Forward-looking Statements
This press release contains “forward-looking
statements”, within the meaning of the safe harbor provisions of
the U.S. Private Securities Litigation Reform Act of 1995, as
amended, that are based on management’s expectations, estimates,
projections and assumptions. Words such as “expects,”
“anticipates,” “plans,” “believes,” “scheduled,” “estimates” and
variations of these words and similar expressions are intended to
identify forward-looking statements. Forward-looking statements
include, but are not limited to, those regarding anticipated growth
and trends in our businesses and markets, industry outlooks and
demand drivers, our investment and growth strategies, our
development of new products and technologies, our business outlook
for current and future periods, our ongoing transformation
initiative and the effects thereof on our operations and financial
results; and other statements that are not historical facts. These
statements and their underlying assumptions are subject to risks
and uncertainties and are not guarantees of future performance.
Factors that could cause actual results to differ materially from
those expressed or implied by such statements include, without
limitation: the level of demand for our products; global economic
and industry conditions; global trade issues, including the ongoing
trade disputes between the U.S. and China, and changes in trade and
export license policies; our dependency on third-party suppliers
and outsourcing partners; the timing of customer orders; our
ability to develop, deliver and support new products and
technologies; our ability to expand our current markets, increase
market share and develop new markets; the concentrated nature of
our customer base; our ability to obtain and protect intellectual
property rights in key technologies; the effects of regional or
global health epidemics, including the effects of the COVID-19
pandemic on the Company’s operations and on those of our customers
and suppliers; our ability to achieve the objectives of operational
and strategic initiatives and attract, motivate and retain key
employees; the variability of results among products and
end-markets, and our ability to accurately forecast future results,
market conditions, and customer requirements; the impact of our
indebtedness, including our convertible senior notes and our capped
call transactions; and other risks and uncertainties described in
our SEC filings on Forms 10-K, 10-Q and 8-K, and from time-to-time
in our other SEC reports. All forward-looking statements speak only
to management’s expectations, estimates, projections and
assumptions as of the date of this press release or, in the case of
any document referenced herein or incorporated by reference, the
date of that document. The Company does not undertake any
obligation to update or publicly revise any forward-looking
statements to reflect events, circumstances or changes in
expectations after the date of this press release.
-financial tables attached-
Veeco
Contacts: |
|
|
|
Investors: |
Anthony Pappone |
(516) 500-8798 |
apappone@veeco.com |
Media: |
Kevin Long |
(516) 714-3978 |
klong@veeco.com |
|
|
|
|
Veeco Instruments Inc. and Subsidiaries |
Condensed Consolidated Statements of
Operations |
(in thousands, except per share amounts) |
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended June 30, |
|
Six months ended June 30, |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
Net sales |
$ |
161,641 |
|
|
$ |
163,999 |
|
|
$ |
315,145 |
|
|
$ |
320,425 |
|
Cost of sales |
|
94,131 |
|
|
|
99,732 |
|
|
|
185,618 |
|
|
|
190,146 |
|
Gross profit |
|
67,510 |
|
|
|
64,267 |
|
|
|
129,527 |
|
|
|
130,279 |
|
Operating expenses, net: |
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
27,384 |
|
|
|
26,016 |
|
|
|
54,945 |
|
|
|
50,133 |
|
Selling, general, and administrative |
|
23,822 |
|
|
|
22,950 |
|
|
|
46,449 |
|
|
|
45,844 |
|
Amortization of intangible assets |
|
2,123 |
|
|
|
2,505 |
|
|
|
4,235 |
|
|
|
5,009 |
|
Other operating expense (income), net |
|
493 |
|
|
|
(27 |
) |
|
|
404 |
|
|
|
(47 |
) |
Total operating expenses,
net |
|
53,822 |
|
|
|
51,444 |
|
|
|
106,033 |
|
|
|
100,939 |
|
Operating income |
|
13,688 |
|
|
|
12,823 |
|
|
|
23,494 |
|
|
|
29,340 |
|
Interest expense, net |
|
(632 |
) |
|
|
(2,635 |
) |
|
|
(1,434 |
) |
|
|
(5,438 |
) |
Other income (expense), net |
|
(97,091 |
) |
|
|
— |
|
|
|
(97,091 |
) |
|
|
— |
|
Income (loss) before income
taxes |
|
(84,035 |
) |
|
|
10,188 |
|
|
|
(75,031 |
) |
|
|
23,902 |
|
Income tax expense (benefit) |
|
1,285 |
|
|
|
533 |
|
|
|
1,548 |
|
|
|
917 |
|
Net income (loss) |
$ |
(85,320 |
) |
|
$ |
9,655 |
|
|
$ |
(76,579 |
) |
|
$ |
22,985 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) per common
share: |
|
|
|
|
|
|
|
|
|
|
|
Basic |
$ |
(1.61 |
) |
|
$ |
0.19 |
|
|
$ |
(1.48 |
) |
|
$ |
0.46 |
|
Diluted |
$ |
(1.61 |
) |
|
$ |
0.18 |
|
|
$ |
(1.48 |
) |
|
$ |
0.43 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of
shares: |
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
52,861 |
|
|
|
49,697 |
|
|
|
51,764 |
|
|
|
49,702 |
|
Diluted |
|
52,861 |
|
|
|
59,455 |
|
|
|
51,764 |
|
|
|
59,521 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Veeco Instruments Inc. and Subsidiaries |
Condensed Consolidated Balance Sheets |
(in thousands) |
|
|
June 30, |
|
December 31, |
|
2023 |
|
2022 |
|
(unaudited) |
|
|
|
|
Assets |
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
Cash and cash equivalents |
$ |
180,524 |
|
|
$ |
154,925 |
|
Restricted cash |
|
437 |
|
|
|
547 |
|
Short-term investments |
|
105,875 |
|
|
|
147,488 |
|
Accounts receivable, net |
|
130,140 |
|
|
|
124,221 |
|
Contract assets |
|
20,490 |
|
|
|
16,507 |
|
Inventories |
|
244,470 |
|
|
|
206,908 |
|
Prepaid expenses and other current assets |
|
27,218 |
|
|
|
18,305 |
|
Total current assets |
|
709,154 |
|
|
|
668,901 |
|
Property, plant and equipment,
net |
|
111,993 |
|
|
|
107,281 |
|
Operating lease right-of-use
assets |
|
25,611 |
|
|
|
26,467 |
|
Intangible assets, net |
|
48,192 |
|
|
|
23,887 |
|
Goodwill |
|
214,964 |
|
|
|
181,943 |
|
Deferred income taxes |
|
115,314 |
|
|
|
116,349 |
|
Other assets |
|
3,219 |
|
|
|
3,355 |
|
Total assets |
$ |
1,228,447 |
|
|
$ |
1,128,183 |
|
|
|
|
|
|
|
|
|
Liabilities and
stockholders’ equity |
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
Accounts payable |
$ |
63,212 |
|
|
$ |
52,049 |
|
Accrued expenses and other current liabilities |
|
61,823 |
|
|
|
56,031 |
|
Customer deposits and deferred revenue |
|
156,700 |
|
|
|
127,223 |
|
Income taxes payable |
|
563 |
|
|
|
2,432 |
|
Current portion of long-term debt |
|
— |
|
|
|
20,169 |
|
Total current liabilities |
|
282,298 |
|
|
|
257,904 |
|
Deferred income taxes |
|
6,878 |
|
|
|
1,285 |
|
Long-term debt |
|
274,335 |
|
|
|
254,491 |
|
Long-term operating lease
liabilities |
|
32,838 |
|
|
|
33,581 |
|
Other liabilities |
|
19,498 |
|
|
|
3,098 |
|
Total liabilities |
|
615,847 |
|
|
|
550,359 |
|
|
|
|
|
|
|
|
|
Total stockholders’ equity |
|
612,600 |
|
|
|
577,824 |
|
Total liabilities and stockholders’ equity |
$ |
1,228,447 |
|
|
$ |
1,128,183 |
|
|
|
|
|
|
|
|
|
Note on Reconciliation Tables
The below tables include financial measures
adjusted for the impact of certain items; these financial measures
are therefore not calculated in accordance with U.S. generally
accepted accounting principles (“GAAP”). These Non-GAAP financial
measures exclude items such as: share-based compensation expense;
charges relating to restructuring initiatives; non-cash asset
impairments; certain other non-operating gains and losses; and
acquisition-related items such as transaction costs, non-cash
amortization of acquired intangible assets, and certain integration
costs.
These Non-GAAP financial measures may be
different from Non-GAAP financial measures used by other companies.
Non-GAAP financial measures should not be considered a substitute
for, or superior to, measures of financial performance prepared in
accordance with GAAP. By excluding these items, Non-GAAP financial
measures are intended to facilitate meaningful comparisons to
historical operating results, competitors’ operating results, and
estimates made by securities analysts. Management is evaluated on
key performance metrics including Non-GAAP Operating income (loss),
which is used to determine management incentive compensation as
well as to forecast future periods. These Non-GAAP financial
measures may be useful to investors in allowing for greater
transparency of supplemental information used by management in its
financial and operational decision-making. In addition, similar
Non-GAAP financial measures have historically been reported to
investors; the inclusion of comparable numbers provides consistency
in financial reporting. Investors are encouraged to review the
reconciliation of the Non-GAAP financial measures used in this news
release to their most directly comparable GAAP financial
measures.
|
Reconciliation of GAAP to Non-GAAP Financial Data (Q2
2023) |
(in thousands) |
(unaudited) |
|
|
|
|
|
|
Non-GAAP Adjustments |
|
|
|
|
|
|
|
|
|
Share-Based |
|
|
|
|
|
|
|
|
Three months ended June 30, 2023 |
|
GAAP |
|
Compensation |
|
Amortization |
|
Other |
|
Non-GAAP |
Net sales |
|
$ |
161,641 |
|
|
|
|
|
|
|
|
$ |
161,641 |
|
Gross profit |
|
|
67,510 |
|
|
1,572 |
|
|
|
|
— |
|
|
|
69,082 |
|
Gross margin |
|
|
41.8 |
% |
|
|
|
|
|
|
|
|
42.7 |
% |
Operating expenses |
|
|
53,822 |
|
|
(6,360 |
) |
|
(2,123 |
) |
|
(549 |
) |
|
|
44,790 |
|
Operating income |
|
|
13,688 |
|
|
7,932 |
|
|
2,123 |
|
|
549 |
^ |
|
|
24,292 |
|
Net income (loss) |
|
|
(85,320 |
) |
|
7,932 |
|
|
2,123 |
|
|
95,868 |
^ |
|
|
20,603 |
|
_________________________^ - See table below
for additional details.
Other Non-GAAP Adjustments (Q2 2023) |
(in thousands) |
(unaudited) |
|
Three months ended June 30, 2023 |
|
|
Changes in contingent consideration |
$ |
350 |
|
Acquisition related |
|
199 |
|
Subtotal |
|
549 |
|
Non-cash interest expense |
|
288 |
|
Other (income) expense,
net |
|
97,091 |
|
Non-GAAP tax adjustment * |
|
(2,060 |
) |
Total Other |
$ |
95,868 |
|
_________________________* - The ‘with or
without’ method is utilized to determine the income tax effect of
all Non-GAAP adjustments.
Net Income per Common Share (Q2 2023) |
(in thousands, except per share amounts) |
(unaudited) |
|
|
Three months ended June 30, 2023 |
|
GAAP |
|
Non-GAAP |
Numerator: |
|
|
|
|
|
|
Net income (loss) |
$ |
(85,320 |
) |
|
$ |
20,603 |
|
Interest expense associated
with 2025 and 2027 Convertible Senior Notes |
|
— |
|
|
|
1,482 |
|
Net income (loss) available to
common shareholders |
$ |
(85,320 |
) |
|
$ |
22,085 |
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
Basic weighted average shares
outstanding |
|
52,861 |
|
|
|
52,861 |
|
Effect of potentially dilutive
share-based awards |
|
— |
|
|
|
838 |
|
Dilutive effect of 2025
Convertible Senior Notes (1) |
|
— |
|
|
|
3,385 |
|
Dilutive effect of 2027
Convertible Senior Notes (1)(2) |
|
— |
|
|
|
4,152 |
|
Diluted weighted average
shares outstanding |
|
52,861 |
|
|
|
61,236 |
|
|
|
|
|
|
|
|
Net income (loss) per
common share: |
|
|
|
|
|
|
Basic |
$ |
(1.61 |
) |
|
$ |
0.39 |
|
Diluted |
$ |
(1.61 |
) |
|
$ |
0.36 |
|
_________________________(1) - Weighted average based
on number of days outstanding during the period, considering the
debt refinancing transaction on May 19, 2023.
(2) - The non-GAAP incremental dilutive shares
includes the impact of the Company’s capped call transaction issued
concurrently with our 2027 Notes, and as such, an effective
conversion price of $18.46 is used when determining incremental
shares to add to the dilutive share count. The GAAP incremental
dilutive shares does not include the impact of the Company’s capped
call transaction, and as such, an effective conversion price of
$13.98 is used when determining incremental shares to add to the
dilutive share count.
Reconciliation of GAAP to Non-GAAP Financial Data (Q2
2022) |
(in thousands, except per share amounts) |
(unaudited) |
|
|
|
|
|
|
|
Non-GAAP Adjustments |
|
|
|
|
|
|
|
|
|
|
Share-based |
|
|
|
|
|
|
|
Three months ended June 30, 2022 |
|
GAAP |
|
Compensation |
|
Amortization |
|
Other |
|
Non-GAAP |
Net sales |
|
$ |
163,999 |
|
|
|
|
|
|
|
|
$ |
163,999 |
|
Gross profit |
|
|
64,267 |
|
|
1,251 |
|
|
|
|
654 |
|
|
|
66,172 |
|
Gross margin |
|
|
39.2 |
% |
|
|
|
|
|
|
|
|
40.3 |
% |
Operating expenses |
|
|
51,444 |
|
|
(5,027 |
) |
|
(2,505 |
) |
|
(719 |
) |
|
|
43,193 |
|
Operating income |
|
|
12,823 |
|
|
6,278 |
|
|
2,505 |
|
|
1,373 |
^ |
|
|
22,979 |
|
Net income |
|
|
9,655 |
|
|
6,278 |
|
|
2,505 |
|
|
1,537 |
^ |
|
|
19,975 |
|
_________________________^ - See table below
for additional details.
Other Non-GAAP Adjustments (Q2 2022) |
(in thousands) |
(unaudited) |
|
Three months ended June 30, 2022 |
|
|
Transition expenses related to San Jose expansion project |
$ |
1,313 |
|
Depreciation of PP&E fair
value step-up associated with the Ultratech purchase
accounting |
|
60 |
|
Subtotal |
|
1,373 |
|
Non-cash interest expense |
|
239 |
|
Non-GAAP tax adjustment * |
|
(75 |
) |
Total Other |
$ |
1,537 |
|
_________________________* - The ‘with or
without’ method is utilized to determine the income tax effect of
all Non-GAAP adjustments.
Net Income per Common Share (Q2 2022) |
(in thousands, except per share amounts) |
(unaudited) |
|
|
Three months ended June 30, 2022 |
|
GAAP |
|
Non-GAAP |
Numerator: |
|
|
|
|
|
|
|
Net income |
$ |
9,655 |
|
|
$ |
19,975 |
|
Interest expense associated
with convertible notes |
|
1,273 |
|
|
|
2,467 |
|
Net income available to common
shareholders |
$ |
10,928 |
|
|
$ |
22,442 |
|
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
|
Basic weighted average shares
outstanding |
|
49,697 |
|
|
|
49,697 |
|
Effect of potentially dilutive
share-based awards |
|
816 |
|
|
|
816 |
|
Dilutive effect of 2023
Convertible Senior Notes |
|
— |
|
|
|
504 |
|
Dilutive effect of 2025
Convertible Senior Notes |
|
— |
|
|
|
5,521 |
|
Dilutive effect of 2027
Convertible Senior Notes (1) |
|
8,942 |
|
|
|
6,771 |
|
Diluted weighted average
shares outstanding |
|
59,455 |
|
|
|
63,309 |
|
|
|
|
|
|
|
|
|
Net income per common
share: |
|
|
|
|
|
|
|
Basic |
$ |
0.19 |
|
|
$ |
0.40 |
|
Diluted |
$ |
0.18 |
|
|
$ |
0.35 |
|
_________________________(1) - The
non-GAAP incremental dilutive shares includes the impact of the
Company’s capped call transaction issued concurrently with our 2027
Notes, and as such, an effective conversion price of $18.46 is used
when determining incremental shares to add to the dilutive share
count. The GAAP incremental dilutive shares does not include the
impact of the Company’s capped call transaction, and as such, an
effective conversion price of $13.98 is used when determining
incremental shares to add to the dilutive share count.
Reconciliation of GAAP Net Income to Non-GAAP Operating
Income (Q2 2023 and 2022) |
(in thousands) |
(unaudited) |
|
|
Three months ended |
|
Three months ended |
|
June 30, 2023 |
|
June 30, 2022 |
GAAP Net income (loss) |
$ |
(85,320 |
) |
|
$ |
9,655 |
|
Share-based compensation |
|
7,932 |
|
|
|
6,278 |
|
Amortization |
|
2,123 |
|
|
|
2,505 |
|
Transition expenses related to
San Jose expansion project |
|
— |
|
|
|
1,313 |
|
Depreciation of PP&E fair
value step-up associated with the Ultratech purchase
accounting |
|
— |
|
|
|
60 |
|
Changes in contingent
consideration |
|
350 |
|
|
|
— |
|
Acquisition related |
|
199 |
|
|
|
— |
|
Interest (income) expense,
net |
|
632 |
|
|
|
2,635 |
|
Other (income) expense,
net |
|
97,091 |
|
|
|
— |
|
Income tax expense
(benefit) |
|
1,285 |
|
|
|
533 |
|
Non-GAAP Operating income |
$ |
24,292 |
|
|
$ |
22,979 |
|
|
|
|
|
|
|
|
|
Reconciliation of GAAP to Non-GAAP Financial Data (Q3
2023) |
(in millions, except per share amounts) |
(unaudited) |
|
|
|
|
|
|
|
|
|
Non-GAAP Adjustments |
|
|
|
|
|
|
Guidance for the three
months ending |
|
|
|
|
|
|
|
Share-based |
|
|
|
|
|
|
|
|
|
|
September 30, 2023 |
|
GAAP |
|
Compensation |
|
Amortization |
|
Other |
|
Non-GAAP |
Net sales |
|
$ |
155 |
|
- |
$ |
175 |
|
|
|
|
|
|
|
|
$ |
155 |
|
- |
$ |
175 |
|
Gross profit |
|
|
63 |
|
- |
|
73 |
|
|
2 |
|
|
— |
|
|
— |
|
|
|
65 |
|
- |
|
75 |
|
Gross margin |
|
|
41 |
% |
- |
|
42 |
% |
|
|
|
|
|
|
|
|
42 |
% |
- |
|
43 |
% |
Operating expenses |
|
|
53 |
|
- |
|
55 |
|
|
(6 |
) |
|
(2 |
) |
|
— |
|
|
|
45 |
|
- |
|
47 |
|
Operating income (loss) |
|
|
10 |
|
- |
|
17 |
|
|
8 |
|
|
2 |
|
|
— |
|
|
|
20 |
|
- |
|
27 |
|
Net income (loss) |
|
$ |
9 |
|
- |
$ |
15 |
|
|
8 |
|
|
2 |
|
|
(2 |
) |
|
$ |
17 |
|
- |
$ |
23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) per diluted common
share |
|
$ |
0.16 |
|
- |
$ |
0.27 |
|
|
|
|
|
|
|
|
$ |
0.30 |
|
- |
$ |
0.40 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income per Diluted Common Share (Q3
2023) |
(in millions, except per share amounts) |
(unaudited) |
|
Guidance for the three months ending September 30,
2023 |
|
GAAP |
|
Non-GAAP |
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
9 |
- |
$ |
15 |
|
$ |
17 |
- |
$ |
23 |
Interest expense associated
with convertible notes |
|
|
— |
|
|
1 |
|
|
1 |
|
|
1 |
Net income (loss) available to
common shareholders |
|
$ |
9 |
- |
$ |
16 |
|
$ |
18 |
- |
$ |
24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic weighted average shares
outstanding |
|
|
55 |
|
|
55 |
|
|
55 |
|
|
55 |
Effect of potentially dilutive
share-based awards |
|
|
1 |
|
|
1 |
|
|
1 |
|
|
1 |
Dilutive effect of 2025
Convertible Senior Notes |
|
|
— |
|
|
1 |
|
|
1 |
|
|
1 |
Dilutive effect of 2027
Convertible Senior Notes (1) |
|
|
2 |
|
|
2 |
|
|
2 |
|
|
2 |
Diluted weighted average
shares outstanding |
|
|
58 |
|
|
59 |
|
|
59 |
|
|
59 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per
common share: |
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) per diluted
common share |
|
$ |
0.16 |
- |
$ |
0.27 |
|
$ |
0.30 |
- |
$ |
0.40 |
_________________________
(1) - The non-GAAP incremental dilutive
shares includes the impact of the Company’s capped call transaction
issued concurrently with our 2027 Notes, and as such, an effective
conversion price of $18.46 is used when determining incremental
shares to add to the dilutive share count. The GAAP incremental
dilutive shares does not include the impact of the Company’s capped
call transaction, and as such, an effective conversion price of
$13.98 is used when determining incremental shares to add to the
dilutive share count.
Reconciliation of GAAP Net Income to Non-GAAP Operating
Income (Q3 2023) |
(in millions) |
(unaudited) |
|
Guidance for the three months ending September 30,
2023 |
|
|
|
|
|
|
GAAP Net income (loss) |
|
$ |
9 |
- |
$ |
15 |
Share-based compensation |
|
|
8 |
- |
|
8 |
Amortization |
|
|
2 |
- |
|
2 |
Income tax expense
(benefit) |
|
|
1 |
- |
|
2 |
Non-GAAP Operating income |
|
$ |
20 |
- |
$ |
27 |
Note: Amounts may not calculate precisely due to
rounding.
Veeco Instruments Inc DE (NASDAQ:VECO)
Historical Stock Chart
From Apr 2024 to May 2024
Veeco Instruments Inc DE (NASDAQ:VECO)
Historical Stock Chart
From May 2023 to May 2024